Regeneron (RGO) Earnings Dates, Call Summary & Reports

Q: What is the P/E ratio of Regeneron stock?

The P/E ratio of {name} is N/A.

3 Followers

Earnings Data

Report Date

Apr 29, 2026

Before Open (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

7.61

Last Year’s EPS

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 23 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Jan 30, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed substantial commercial strength (notably Dupixent, EYLEA HD, Libtayo), solid financials, strong cash generation, aggressive shareholder returns, and a deep pipeline with multiple near‑term readouts and regulatory objectives. Headwinds were acknowledged — including EYLEA 2 mg biosimilar pressure, short‑term inventory timing, manufacturing/regulatory risk for the prefilled syringe, patient affordability challenges, and higher R&D and SG&A investments. On balance, the positives — large, high‑growth franchises, robust cash flow, and multiple potentially transformative clinical programs — materially outweigh the near‑term challenges and risks discussed.

Company Guidance

Regeneron guided 2026 financials expecting R&D spend of $5.9–$6.1 billion, SG&A of $2.5–$2.65 billion, gross margin on net product sales of 83%–84%, capital expenditures of $1.1–$1.3 billion, and an effective tax rate of 13%–15% (noting 2025’s ETR benefited ~1.2 percentage points from a favorable audit). Management expects the Sanofi development balance (just below $600 million at year‑end, down ~ $300 million since Q3 and with >$1 billion reimbursed in 2025) to be fully reimbursed by mid‑2026, after which collaboration revenues will reflect Regeneron’s full share of Dupixent/Kevzara profits. For context, Regeneron generated $4.1 billion of free cash flow in 2025, finished the year with $16.2 billion cash and marketable securities less debt, returned $3.8 billion to shareholders in 2025 (including $3.4 billion of repurchases with ~$1.5 billion remaining authorization), paid nearly $400 million in dividends and authorized a quarterly dividend of $0.94 per share ($3.76 annualized).

Overall Financial Performance

Q4 2025 total revenues $3.9B, up 3% year-over-year; Q4 diluted net income per share $11.44 and net income $1.2B; 2025 free cash flow $4.1B; cash and marketable securities less debt $16.2B.

Dupixent Strong Growth and Scale

Global Dupixent net product sales $4.9B in Q4 (+32% YoY) and $17.8B for FY2025; U.S. net sales up 36% YoY to $3.7B; >1.4M patients on therapy; approved in 80 indications, many underpenetrated.

EYLEA HD Rapid Momentum

U.S. EYLEA HD net sales $506M in Q4, up 66% YoY and $1.6B for FY2025 (+36% YoY); EYLEA HD represented ~50% of Regeneron's anti‑VEGF franchise; 18% sequential growth quarter-over-quarter and physician demand +10% vs Q3.

Libtayo Commercial Progress

Global Libtayo net sales $425M in Q4 (+13% YoY at constant currency) and $1.45B for FY2025; U.S. net sales $285M, up 14% YoY; launched in adjuvant CSCC with strong early uptake and added as NCCN category 1 preferred in that setting.

Strong Collaboration and Royalty Streams

Sanofi collaboration revenues ~ $1.6B in Q4 with Regeneron share of profits up 42% YoY; other revenue up 33% in Q4 to $239M (including royalties); Alaris net sales >$1.5B in 2025 achieving top royalty tier (15%).

Capital Deployment and Shareholder Returns

Returned $3.8B to shareholders in 2025 (including $3.4B share repurchases); $1.5B remaining repurchase authorization; initiated quarterly dividend with new quarterly dividend $0.94/share (annualized $3.76).

Robust Pipeline and Near-Term Milestones

Company expects at least four FDA approvals in next 12 months (including 3 NMEs and EYLEA HD prefilled syringe); plans to initiate 18 additional Phase III studies (target enrollment ~35,000); multiple pivotal readouts in 2026 across oncology, ophthalmology, complement, hematology and obesity.

Notable Clinical Data and Program Highlights

Lenazipic (BCMA×CD3) shows high complete response and MRD‑negativity (100% MRD‑negativity in evaluable newly diagnosed/ high‑risk smoldering cohorts cited); cendicia in gMG showed placebo‑adjusted improvement of 2.3 in MG‑ADL at 24 weeks; PNH combination showed 96% control in pivotal cohort; DV gene therapy produced meaningful hearing gain in 11/12 children; FOP program showed >99% reduction in abnormal bone formation at 56 weeks.

Regeneron (DE:RGO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:RGO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 29, 2026	2026 (Q1)	7.61 / -	6.998	―	―	―
Jan 30, 2026	2025 (Q4)	9.14 / 9.74	10.275	-5.22% (-0.54)
Oct 28, 2025	2025 (Q3)	8.22 / 10.07	10.607	-5.06% (-0.54)
Aug 07, 2025	2025 (Q2)	7.18 / 10.97	9.841	11.51% (+1.13)
Apr 29, 2025	2025 (Q1)	7.34 / 7.00	8.13	-13.93% (-1.13)
Feb 04, 2025	2024 (Q4)	9.60 / 10.28	10.097	1.77% (+0.18)
Oct 31, 2024	2024 (Q3)	9.96 / 10.61	9.867	7.51% (+0.74)
Aug 01, 2024	2024 (Q2)	9.04 / 9.84	8.718	12.89% (+1.12)
May 02, 2024	2024 (Q1)	8.66 / 8.13	8.59	-5.35% (-0.46)
Feb 02, 2024	2023 (Q4)	9.14 / 10.10	10.693	-5.57% (-0.60)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DE:RGO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jan 30, 2026	€623.45	€618.06	-0.87%
Oct 28, 2025	€498.98	€525.72	+5.36%
Aug 07, 2025	€488.85	€473.61	-3.12%
Apr 29, 2025	€532.68	€486.54	-8.66%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.